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High-tech businesses are the driving force behind global knowledge-based economies. Academic institu-
tions have positioned themselves to serve the high-tech industry through consulting, licensing, and univer-
sity spinoffs. The awareness of commercialization strategies and building an entrepreneurial culture can
help academics to efficiently transfer their inventions to the market to achieve the maximum value. Here,
the concept of high-tech entrepreneurship is discussed from lab to market in technology-intensive sectors
such as nanotechnology, photonics, and biotechnology, specifically in the context of lab-on-a-chip
devices. This article provides strategies for choosing a commercialization approach, financing a startup,
marketing a product, and planning an exit. Common reasons for startup company failures are discussed
and guidelines to overcome these challenges are suggested. The discussion is supplemented with case
studies of successful and failed companies. Identifying a market need, assembling a motivated manage-
ment team, managing resources, and obtaining experienced mentors lead to a successful exit.1. The university entrepreneur
The era of global entrepreneurship offers worldwide trade,
international capital and investment, intercontinental supply
chains, migration of talent, and expansion of knowledge-
based economies. The integration of international economies
has resulted in open policies, liberalization of trade and
advances in transport and communication. The multinational
businesses in the developed world are now challenged by the
new global players emerging from the BRIC (Brazil, Russia,
India and China) economies. The realization of foreign direct
investment and increasing export of expertise are vitalchannels for global integration and technology transfer
through multinational corporations. Knowledge spillovers
from academic institutions to private industry are major driv-
ing force behind economic growth and increase in welfare.1–3
Increasing investment in research is an incentive for universi-
ties to raise revenues by licensing intellectual property (IP)
and spinning off companies.4 The focus of technology trans-
fer is directed to exploitation of comparative advantages
within global competition. Hence, optimization of technology
transfer from academic institutions to industry and creating
high-value products through university spinoffs has become a
necessity for fueling economic growth (Fig. 1). This trend also
represents a shift away from physical assets to knowledge and
intangible assets such as human capital.5oyal Society of Chemistry 2015
mpany in knowledge-based
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View Article OnlineThe high-tech industries include photonics, nanotechnol-
ogy, biotechnology, artificial intelligence, semiconductors,
robotics, and telecommunications.6–18 These sectors require
smaller, lighter, faster, more efficient and functional compo-
nents at the nano/microscales. This demand gave rise to min-
iaturized self-contained and high-throughput micro-
electromechanical systems, lab-on-a-chip components and
microfluidics to transform the way researchers investigate
and gain insight into fundamental chemical, physical and
biological processes.19 These fields lie at the interface of engi-
neering, physics, chemistry and biology and offer promise in
the development of practical lab-on-a-chip systems for appli-
cations in single cell analysis,20 drug discovery,21 genetics
and proteomics,22 environmental monitoring,23 plant sci-
ences,24 and point-of-care diagnostics.25,26 High-tech entre-
preneurship involves creating a new business by turning anThis journal is © The Royal Society of Chemistry 2015
Fig. 2 Roadmap for the commercialization of inventions in high-tech businidea into a high-potential commercial product, gathering
resources such as co-founders and financial capital, develop-
ing commercialization and marketing strategies, and manag-
ing the growth of the enterprise (Fig. 2).
The efficient transfer of emerging technologies from aca-
demic institutions to industry requires entrepreneurial cul-
ture, optimized licensing strategies, strong academia-industry
partnership, and organizational support to spin-off compa-
nies.27,28 While the mission of academic institutions is to
exchange knowledge by supporting basic scientific discover-
ies, they also focus on commercial initiatives. For example,
the mission of the Wyss Institute and Innovation Lab at Har-
vard is to translate ideas into products by developing proto-
types, validating them against market needs, forming
startups, and building corporate alliances. The Vice Provost
for Research at Harvard, Professor Richard McCullough,Lab Chip, 2015, 15, 3638–3660 | 3639
esses.
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View Article Onlinestated that the university has adopted an aggressive commer-
cialization strategy over the last decade. The university spins
off about 10 companies per year, and 20–40 students pursue
entrepreneurial careers each year. However, MIT has histori-
cally been focused on the advancement of industrial science
and commercialization of inventions. In 2013, they launched
the Innovation Initiative, which is an institute-wide program
that focuses on expanding MIT's innovation capabilities to
solve critical challenges in medicine, environmental issues,
and energy. Across the Atlantic, the University of Cambridge
established Cambridge Innovation Capital (CIC) to in invest
in high-growth technology companies in the Cambridge
high-tech cluster. CIC utilizes a longer-term investment
approach to support businesses through to maturity without
having to provide early exits for investors. These examples
are indicative of the commercialization awareness in aca-
demic institutions that has become an integral part of
knowledge-based economies.
Here, the evolution of a university spin-off company from
idea to exit is discussed, and technology transfer strategies
are outlined. Potential pitfalls are identified, and practical
strategies to create a successful startup company are
described. These strategies are supplemented with case stud-
ies that describe failed and successful startups. Furthermore,
this article investigates the role of innovation-driven enter-
prise, where the entrepreneurs focus on global markets.
While a substantial amount of innovation in high-tech indus-
tries exists outside of the academia, this article discusses the
university entrepreneurship.
2. The startup company
Entrepreneurship involves obtaining IP protection, develop-
ing and adopting a commercialization strategy, turning the
proof-of-concept technology into a marketable product,
financing the business, marketing the product, and deter-
mining an exit strategy.29 The co-founders should accordingly
determine the vision of their company and products that
address the specific needs of a market.2.1. Intellectual property protection
The first step in commercialization is protecting IP. Academic
researchers can consult their university's technology transfer
office (TTO), which can assist in determining the scope of
the patent and developing its claims. Once the TTO and the
academicĲs) mutually agree to proceed with a patent and no
prior art is found, TTO assigns the project to an in-house or
outside attorney to prepare and file a patent application. The
claims are then drafted according to the proposed business
plan. TTOs arose to bridge the gap between the differing
incentives of the researchers and the firms. University and
government laboratories are incentivized by the maximiza-
tion of impact of the research results. Firms that use this
knowledge, on the other hand, are typically driven by maxi-
mization of profit and commercial measures.303640 | Lab Chip, 2015, 15, 3638–3660The United States government creates economic incentives
for universities to commercialize their research. IP is thus
commonly awarded to the university rather than the individ-
ual. Prior to 1980, inventions that resulted from federally
funded research were controlled by the government. After the
passage of the Bayh-Dole Act, however, the ownership of this
IP was handed to the universities and businesses to foster
commercialization.4,31 Therefore, in the United States, TTOs
are typically an integral part of the institution. Researchers
should consult the TTOs as early as possible so that sufficient
time can be spent developing the patent before publication.
While most TTOs in the United States provide licensing
advice, some institutions such as Cornell's Center for Tech-
nology Licensing also provides consultation in startup com-
mercialization and marketing.
In Europe, most academic patents are assigned to compa-
nies, followed by universities, public research organizations,
and individual inventors.32 However, the distribution of
patent ownership, their respective legal norms on IP and
institutional policies differ across European countries.33
With the exception of Italy and Sweden, the IP rights are not
assigned to academic inventors.34 In Europe, some TTOs are
subsidiaries of universities. At the University of Cambridge,
for example, the academic inventors can choose to opt out of
working with Cambridge Enterprise Ltd.35 In this case, Cam-
bridge Enterprise does not manage the IP and licensing, and
IP rights are assigned to the inventor. This option also allows
the students to own their IP unless bound by a third party
agreement. As another example, the Swedish government
has attempted to foster innovation by spending $3.8b on
research and development (R&D) in 2014.36 However, the
success of their academic-based startups is limited, and
the United States patenting model is suggested to be more
effective in promoting the commercialization of academic
research.37
The number of patents granted to universities in the
United States increased from less than 300 in 1980 to 5700 in
2013, while licensing revenue generated by these patents rose
from $160m in 1991 to over $2.6b in 2013.38,39 The life sci-
ences accounted for the majority of incoming revenue, outgo-
ing licenses, and startups.40 This pattern is also evident
across Europe as well as Australia and Canada, indicative of
the increasing importance of the role of TTOs in commercial-
ization.41 Regardless of the model, IP protection should be
developed in parallel to research. Although it is not required
to provide experimental data for filing a patent application,
the concepts should be tested and validated to obtain
blocking patents.272.2. Commercialization strategy
Technology entrepreneurs must formulate and implement a
commercialization strategy that determines the ultimate per-
formance of the business. Table 1 presents selected entre-
preneurship and commercialization strategies, their key
attributes and the founding team's respective levels ofThis journal is © The Royal Society of Chemistry 2015
Table 1 Entrepreneurship and commercialization strategies and their keys attributes, and respective levels of commitment and time horizon for the
business
Strategy Key attributes
Asset commitment
(%)
Time horizon
(years)
Sale/licensing of IP Cede the right to innovation; remain independent 10 1
External development aimed at acquisition Focus resources externally; no longer independent 15 1–2
Internal development (including external cooperations) Retain the equity and independence 90 5–10+
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View Article Onlinecommitment and time horizon for the business. This table
primarily covers high-tech technologies such as medical, vet-
erinary, environmental diagnostics, and analytical devices,
and it excludes long-term technologies involving drug discov-
ery. The timeframes can be shorter or longer depending on
the type of product and market involved. While inexperienced
innovators may have a “build it and they will come” mental-
ity, experienced entrepreneurs and investors understand that
the innovation itself, regardless of its scientific merit, is only
a piece of product development, which determines the
company's ultimate commercial success. Commercialization
typically follows one of three primary strategic paths: (1) sale
or licensing of IP, (2) external development focused on acqui-
sition, (3) internal development of a startup aimed at an ini-
tial public offering (IPO), or a mix of these strategies.
If the inventor does not want to be involved in the com-
mercialization process, he/she can sell the rights to the inno-
vation to another company. The inventor may choose to offer
the company technical assistance in exchange for a set cost,
royalties, or other agreement. IP can also be licensed if the
inventor wants to maintain ownership of the patent(s) but
does not have the commitment or time to be involved in the
company. Although the terms of a licensing agreement vary
for each technology, firm, and environment, the defining
feature of this arrangement is that both parties remain inde-
pendent while cooperating in commercialization of the tech-
nology.42 An advantage of this strategy is the limited involve-
ment of the founder(s) in terms of time and resources;
however, the technology may never be brought to market in
this scenario if the third party is interested in using but not
necessarily commercializing the technology. Standard license
agreements include negotiated financial terms such as
annual fees, a royalty on product sales, reimbursement of
patent costs, and possibly a minority share of equity in the
startup.43 Additionally, license agreements include non-
financial terms such as the degree of exclusivity (e.g.,
nonexclusive, exclusive, or restricted by field of use), reserva-
tions of the rights for the federal government, and perfor-
mance (diligence) requirements for having the capability to
develop the technology.
Another strategy of commercialization is developing the
startup externally with the goal of eventually being acquired
by another company. In this strategy, the innovator relin-
quishes the independent operation of the startup and gives
the rights to commercialization and control of the technology
to a third party. The innovator recognizes that s/he needs
immediate access to assets to achieve presence in a newThis journal is © The Royal Society of Chemistry 2015market, such as manufacturing economies of scale or gaining
access to a complementary technology or product for the
startup's portfolio. For this type of strategy, the innovator is
not willing to commit the time necessary to develop these
assets internally but generally has the financial means to
acquire these assets externally. For example, rather than
spending the time to develop and optimize a manufacturing
process, the innovator may hire an external manufacturer to
mass produce the product until the startup is acquired by a
larger company. Therefore, the innovator in this case is will-
ing to spend more on the convenience of shorter develop-
ment times.
Internal development is costly and requires the largest
time commitment. In internal development, the innovator
must be prepared to commit up to 90% of his/her available
assets. The innovator must be able to sustain the develop-
ment effort through the life cycle of the business with finan-
cial returns potentially only being realized after over 5 or
more years. In this scenario, the innovator and his/her man-
agement team continues researching, fabricating, and opti-
mizing designs and processes. Internally, the researchers
may de-risk the technology as they develop it further, making
it more attractive to investors. However, most startups do not
have the available funding to bring the product to the inflec-
tion point, where adding a small amount of time and
resources results in a significant improvement in perfor-
mance. Contracting relationships often form during this
stage, including joint ventures and strategic alliances, and
outsourcing may be used to gain access to additional assets.
While each type of external partnership involves different
terms, every form of cooperation impacts investment of cost
and time of the startup in downstream commercialization.
The commercialization strategy of a company is affected
primarily by the company's vision, business philosophy, the
stage of technological development, market risk, competitive
activities and window of opportunity. Ultimately, the optimal
commercialization strategy depends on the innovator's back-
ground and willingness to invest time and resources to have
an independent company and desire to maximize commercial
availability of the innovation.442.3. Productization
Product development involves taking an idea to manufactur-
ing. Productization is the process of analyzing the customer
needs in a target market, designing the product, and develop-
ing manufacturing capability.45 Productization requiresLab Chip, 2015, 15, 3638–3660 | 3641
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View Article Onlineturning intangible services into standardized outcomes
aimed at mass markets. The manufacturer should aim to cre-
ate a standardized output that enables scalability. Addition-
ally, the company should create an extended product that
provides complementary assets, delivers customer value, and
is easily comprehended by customers. The aim of the
productization is to package the high-tech device or service
so that the customer can understand the context, benefits,
and the outcome in advance. Productization includes describ-
ing, improving, manufacturing, and continuously developing
the technology to maximize the customer benefits. In this
way, productization links new product development and
marketing.
Productization can be categorized as inbound (ability to
make) and outbound (ability to sell) approaches. The
inbound productization involves systemizing the offering
delivery process and its outcome within a company.46 For
example, product data management methods can reduce rou-
tine engineering work and help the product reach the market
quickly.47 Reducing the routine work via creating existing
templates, modules and platforms can allow more room for
innovation within the company. However, a high-tech com-
pany should strike a balance between standardization and
customization. Considerable development effort is needed to
transform a prototype into the technical maturity of a core
product, where the development work should be the main
focus of inbound productization. While testing programs
may initially deal with functionality, product development
focuses on robustness and reliability. Technical aspects of
productization may include final design specifications, mate-
rial selection and sourcing, production tools, assembly
instructions, manufacturing strategies, testing, quality con-
trol, and certifications.45 While proof of concepts and func-
tional prototypes are necessary during development stage,
they are not sufficient for a company to have a product.
Hence, the productization aims to create a product portfolio
that is amenable to mass-customization. Ideally, entrepre-
neurs should create a platform technology that is compatible
with customizable products. Hence, the company can use
existing infrastructure to manufacture a variety of products
and conserve capital costs.
Outbound productization aims to increase the visibility of
the completeness of the offered product or service for the
customers. It also increases the value of the product per-
ceived by customers. Other factors such as brand, product
shape, and training can add value to the product. Hence, at
the early stages of the new product design, end customer
requirements should be understood by the company, and the
products should be designed for the target market's needs.
In creating the extended product, platform thinking and
mass tailoring should be utilized to offer a broader product
portfolio.48,49 However, focusing on the core technology may
lead to overengineering the product. A product represents the
totality of the physical product and the service, as well as per-
ceptions, usefulness, desirability and convenience since all
these factors play an important role in the purchasing3642 | Lab Chip, 2015, 15, 3638–3660decision. Creating the concept of the extended product needs
to be incorporated to the early stages of product develop-
ment, where the tasks need to be performed in cross-
functional teams. Therefore, the technology represents a
potential opportunity, the core product is the realization of
this potential, and the extended product is a marketable
product with high performance, customer value, and worth.
In this context, the customer can compare the offering to
other products in the market and judge whether the price
and benefit ratio justifies the purchase.
Creating interfaces between R&D, marketing, sales, and
manufacturing teams is required to achieve the key premises
behind productization.50 The outputs of internal
productization include the deliverables for the costumer and
the strategy to organize the process of creating these deliver-
ables. The outputs of outbound productization is a well-
defined offering, the ability communicate the innovation to
the customer by showing that the company understands its
customer requirements and create the product accordingly.
Productization can also reduce the costs associated with inef-
ficient customer-specific tailoring of the products by revising
the offering and adding modularity. Another benefit of
productization is to create a synergy between research &
development and marketing teams and create a common lan-
guage to discuss their problems with each other. The out-
bound productization allows the company to evaluate the
extended product and services to persuade the customer to
make a buying decision. Hence, productization can be uti-
lized as a framework to analyze extended product creation in
a systematic way. For example, the Dolomite Centre Ltd.
(Royston, UK) specializes in the productization of micro-
fluidic technologies. It recently commercialized Mitos Dropix
Droplet Splitting System under exclusive sub-licence with
Drop-Tech Ltd. (Cambridge, UK).51,52 Dolomite has also
partnered with Sphere Fluidics (Cambridge, UK) and com-
mercialized their PDMS picodroplet handling chips (Pico-
Gen) and surfactants (Pico-Break/Glide/Surf).53
3. Funding
3.1. Financing in the United States
Companies need financial support and capital for research,
product prototyping, manufacturing, licensing, maintaining
their patent portfolio, accounting fees, marketing costs, and
payroll expenses. Co-founders should estimate these various
costs of startup expenses at every stage of company develop-
ment, which involves different levels of risk and investment
(Fig. 3). Even in the idea phase of the startup, expenses start
to accumulate; thus, co-founders should use accounting
worksheets to plan the startup costs. In these lists, compa-
nies should analyze expenses, assets, and financing options.
Expenses cover legal fees, consultants, insurance, and over-
head fees. Assets may include cash, inventories, and equip-
ment. Expenses are deductible against income, so companies
can reduce taxable income. Assets, however, are not deduct-
ible. Thus, companies should allocate the startup costs intoThis journal is © The Royal Society of Chemistry 2015
Fig. 3 Companies experience multiple stages of growth ranging from
(1) concept, (2) startup, (3) growth to (4) expansion or late phases.58–60
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View Article Onlinethe proper categories to avoid complications with taxation.
Furthermore, at this stage, co-founders should conserve
money by seeking discounted vendors for raw materials and
working out of shared spaces in low-cost locations.
At the early stages of a startup, the co-founders possess
100% of the company. However, investors typically obtain a
piece of the company, known as equity, in exchange for their
investments.54 Therefore, the more funding that a companyThis journal is © The Royal Society of Chemistry 2015
Fig. 4 An exemplary distribution of shares from startup to IPO stage.accepts, the more the shares become diluted, and share-
holders become co-owners of the company (Fig. 4). Although
co-founders may own a smaller percentage of the company at
later stages, outside investment allows the company to grow,
and the value of individual shares increase dramatically.55,56
Importantly, investors expect a considerable return on their
investment. Typically, to offer competitive advantages, com-
panies should project “10× return” to the investors within at
least 2–6 years of growth depending on the industry.57 For
instance, in the early stages of venture investment (series A),
a company raises $1m in exchange for 20% equity in com-
pany shares. This creates a company value of $5m. For exam-
ple, with 10× return, companies should plan to reach a $50m
valuation within 5 years. However, these business models
should include realistic sales and marketing plans according
to the feasible industry scales. Such business plans claiming
10× return to the venture investors will be an effective way of
attracting more funding to startups.
Financing options depend on the growth stage of the
startup company.61 In the concept phase (seed), federal
grants, family and friends could be the initial sources of
funding. Investors face high risks at this stage, even if the
capital investment is below $250k, rendering it challenging
to attract private sources of funding. Therefore, co-founders
can accept cash from family and friends at this stage either
as a gift or in exchange for 5–10% equity. In this phase, co-
founders devise a proof of concept of the technology and
establish a business model with a financial plan. The
funding in this stage is needed primarily to hire new
employees to accelerate prototyping. Usually, the founder
offers sweat equity (~20–50%) to the new co-founder inLab Chip, 2015, 15, 3638–3660 | 3643
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View Article Onlineexchange for work. If the co-founder owns less than 50% of
the shares, s/he may be less motivated to put effort and time
toward company development.
In the second financing stage, or medium-growth stage A,
co-founders have access to angel investors and some of the
venture capitalists who are interested in investing in a feasi-
ble product that can penetrate into an attractive target mar-
ket.61,62 At this phase, risks become lower and specific
financing demands (>$500k) are well defined to pass to the
next growth stage. Although the risks are lower, more capital
is required to scale up the business operations, and a com-
pany can raise millions of dollars though venture capitalists
and angel investors. During this round, incubators (e.g.,
Cambridge Biolabs, Lab Central, Cambridge Innovation Cen-
ter), accelerators, and excubators (paid incubators) may offer
working space and advisors, sometimes in exchange for 5–
10% equity. During the venture capital round, the company
should have a fully functioning prototype.63 Typically, the
VCs invest more than $500k. Most lab-on-a-chip companies
raise $10–50m by the time their first product receives regula-
tory clearance.26 Case Study 1 about Microchips Biotech, Inc.
presents a microfluidic drug delivery company that has raised
$81m from VC and grants. The venture capital network also
depends on the geographical and strategic location of the
startup company. For instance, some universities generate
more successful startups compared to others due to their
strong academic and venture relations64 or proximity to a bio-
cluster.65 While angel investors and VCs can be a great
source of funds, the co-founders should be cautious and also
consider the amount of equity they wish to retain during this
round. The co-founders might save 20% of the equity for
future employees as a part of an option pool.
There are several options after this stage; for example, the
co-founders can decide to attempt to start making profit, sell
the business, go to venture capital round B and C, or attempt
an IPO.66 This strategy allows raising money from the public
by selling shares in the stock market. At this stage, all the
investors in the company hold restricted stocks. Before sell-
ing the stocks, they have to be verified by the government
which ascertains whether the public can safely invest in the
company. This process is accomplished by preparing the IPO
documentation through investment bankers who are the lead
underwriters and sell the stocks to clients. The investment
bankers typically receive ~7% of the money raised in IPO.67
The company may also choose to obtain funding from
entrepreneurship competitions, grants, loans, or explore
crowdfunding opportunities for projects that directly appeal
to public. For amateur high-tech entrepreneurs, accessing to
angel investors, resources, as well as mentorship is an over-
whelming task. Therefore, for university entrepreneurs, there
are many “business plan competitions” that bridge the gap
between young scientists and high-profile investors.68 Typi-
cally, a collaborative network in between universities and
industrial partners regulate these business competitions.
Organized by Oxbridge Biotech Roundtable, one recent com-
petition is OneStart that has awarded $150k, free lab space,3644 | Lab Chip, 2015, 15, 3638–3660and mentorship to teams.69 Additional entrepreneurship
competitions include MIT 100K, The Global Moot Corp at
UT Austin, LeanModel (San Diego, CA), Cleantech Open,
FinCapDev, and Rice Business Plan competition (ideal). Fur-
thermore, philanthropists, including Bill & Melinda Gates
Foundation, release competitions and opportunities for bio-
technology entrepreneurs. Case Study 2 about Diagnostics for
All (DFA) presents an example of funding a startup through
entrepreneurship competitions.
Federal government grants are mainly awarded in scien-
tific, medical and environmental research, in particular for
high-tech startups or high-growth firms. Table 2 shows
potential funding resources for a startup company. The pro-
posed grants need to be aligned with the federal R&D objec-
tives, and the technical merits and the benefits of the venture
should be geared towards the local and national economy.
However, these grants are tightly controlled and allocated to
businesses that are on the same agenda of a government
agency such as the Department of Defense in the United
States. There are other grant opportunities offered by states
and local governments such as discretionary inventive grants;
however, they are also aligned to agency goals and are limited
to larger companies. An attractive grant opportunity is Small
Business Innovation (SBIR) grant overseen by the Small Busi-
ness Administration (SBA).70,71 In 2010, SBIR awarded ~$2b,
half of which was allocated to businesses employing less than
25 people. This grant is limited to United States-based busi-
nesses with more than 50% American ownership. Case Study
3 about Optofluidics, Inc. describes an example of funding a
startup through federal grants.
Regulated by SBA, the microloan program provides less
than $50k to startup businesses.72,73 The funded micro-
loans, however, average $13k.74 The operation structure
of these loans includes intermediate administers that deter-
mine eligible borrowers. This funding can be spent in the
forms of working capital, inventories, supplies, furniture,
machinery, and equipment, although it cannot be utilized to
pay existing debts. Companies are allowed to pay an SBA
microloan within up to six years based on the interest rate
determined by United States treasury. Getting a small busi-
ness loan has become difficult after the financial crisis in
2008, and the lingering credit crush. This type of funding
requires the bank to evaluate a financial track record show-
ing the ability to repay the lent money.75 The fundamental
difference between this type of funding and the investors is
that banks are not interested in equity investments in small
businesses. However, alternative lending represents a costly,
but quick and hassle-free strategy to obtain necessary funds.
The business owners should demonstrate that their business
is not a risky investment to the loan officer. Additionally, if
the business model is proven and the company is making
profits, the owners can make a case by also providing their
resumes, references, prior track records, and history of pay-
ing back loans or investors. Having a high credit score is also
a determining factor in obtaining loans from banks. There
are also United States SBA loans that can be easier to secureThis journal is © The Royal Society of Chemistry 2015
Table 2 Funding resources for a startup company in the United States, and the European Union and its associated countries
Type Source Program Amount Description Territory
Federal Small business
administration
Loans Max up to $5m average
>$300k
General, micro, equipment,
real estate, disaster
US
Federal State departments
(NIH, NSF, NASA, EPA)
SBIR/STTR $100k–$1.3m Phase I-II-III US
Private Banks Loans & cards $350k–$3.5m Debit US
Private Business networks Angel investor $150k–$2m Equity capital US
Private Business networks Venture Capital >$500k Equity capital US
Private Business networks Customers and
suppliers
Negotiable Per agreement US
Private Business networks Entrepreneurship
competitions
$10k, $100k, $150k and
more
Per agreement US
Private Business networks Donations Negotiable Per agreement US
Private Internet networks Crowdsourcing $7k–$6m Per agreement US
Politico-economic
union
SME
instrument/European
commission
Grant €50k–>€2.50m Phase I-II-III EU and
associated
countries
Politico-economic
union
European investment
bank/InnovFin
Loan and
guarantee
€25k–€7.5m (SME) €300m
(large companies)
Per agreement EU and
associated
countries
Politico-economic
union
FET-open/European
commission
Grant €2m–€4m Per agreement EU and
associated
countries
Politico-economic
union
COSME/European
commission
Grant €2.3b in total Per agreement EU and
associated
countries
Politico-economic
union
Eurostars Grant €1.14b in total last call:
€150m
Per agreement EUREKA
countries
and the EU
Lab on a Chip Critical review
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View Article Onlinethan a standard bank loan. This type of loan is indirectly
funded by SBA that offers a guaranteed loan to the bank,
which can issue the loan to the business to reduce the risk of
the bank.
Another method of raising funds for a startup company is
crowdfunding that involves pitching a new idea or service,
often accompanied with a prototype, to the public through a
social media campaign such as Kickstarter, Inc.76,77 This
campaign shows the idea, how it is developed, and why it is
functional or fun. In recent years, the crowdfunding industry
has raised more than $3b, and it is projected to grow to up to
$90b by 2025.78 Crowdsourcing operates on the basis of
donations, investments, and rewards (Table 3).This journal is © The Royal Society of Chemistry 2015
Table 3 Types of crowdsourcing
Funding type Crowdfunding source Platform
Public Kickstarter Donation
Public Indiegogo Donation
Public WiSeed Donation
Public DoDo funding Reward
Public Seedr Equity inv
Public Consano Donation
Public Poliwogg Equity inv
Public Crowdfunder Investmen
Public Rockethub Donation
Public Somolend Debt-inves
Public Appbackr Donation
Public Quirky Donation
Scientific Petridish.org Donation
Scientific Experiment.com DonationIf none of these fundraising avenues are successful, some
founders fund their companies from their personal belong-
ings, savings, inventories, and consulting to other compa-
nies. This approach, known as bootstrapping, may be risky
especially for entrepreneurs with family responsibilities as
there is a considerable risk that the business faces difficulties
resulting in bankruptcy. Despite these challenges,
bootstrapping might still be an option if some basic guide-
lines are followed. First, these self-funded startups should
aim for their first sales at the early stages of their operations.
This can facilitate some momentum in the startup both
financially and psychologically. Second, these startups should
minimize their spending and conserve as much as cashLab Chip, 2015, 15, 3638–3660 | 3645
Description
Small volume
Small volume
Single holding from individual investments
Biotech investments
estment Minimum 10% equity
Focus on healing diseases
estment Life science companies as investors with $1–4m
t Larger volume
Extra promotion via FuelPad and LaunchPad
tment Loaner through banks
Mobile app development
Influence sharing
Scientific research
Scientific research
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View Article Onlinepossible. Garage startups are examples of these models,
where they save from costs that are related to the expenses
and assets. An effective bootstrapping approach is to run the
startup as a consulting company to fund the development of
the product.3.2. Financing in Europe and its Associated Countries
Startup funding can be obtained through direct and indirect
financing. Direct funding includes grants from the European
Commission that do not require an exchange of equity, while
indirect funding includes loans and equity shareholders
through banks, private investors, and venture capitals. Some
of these funding options need custom planning for each EU
member country, as the funding decisions depend on the
local conditions of financial institutions. More than 90% of
businesses that apply for EU funding fall into the category of
small and medium-sized enterprises (SMEs).79 In the EU
standards, medium sized companies typically employ less
than 250 people with up to €50m turnover, while small sized
companies are composed of 50 employees bounded to €10m
turnover. The European Commission initiated an Executive
Agency for Small and Medium-sized Enterprises (EASME) to
manage several EU entrepreneurship programs. EASME aims
to create a business-friendly environment through promoting
entrepreneurship, internationalization, networking, and pro-
viding access to finance. Some of these EASME programs
include the SME instrument funding under Horizon 2020,
Competitiveness of Enterprises and Small and Medium-sized
Enterprises (COSME), the EU program for the Environment
and Climate action (LIFE), European Maritime and Fisheries
Fund (EMFF), Fast Track to Innovation (FTI) Pilot, Intelligent
Energy program, and the Eco-innovation initiative.80
The Horizon 2020 is a €80b initiative that aims to support
and encourage research and entrepreneurship in the Euro-
pean Research Area and Associated counties from 2014 to
2020.81 This initiative also supports Pan-European research
infrastructures, promotes open access, and encourages gen-
der equality. Together with its initiatives around societal poli-
cies, Horizon 2020 supports early stage high-risk visionary
science and technology projects performed under SMEs.
Thus, Horizon 2020 dedicated an SME Instrument funding
scheme that aims to fund projects involving information and
communications technology, nanotechnology, and biotech-
nology.82 This funding strategy allows SME businesses to
develop their ideas, and build prototypes, validate the prod-
ucts, obtain customer feedback, and commercialize their
products. The program will invest a total of €3b in high-
potential SEMs to develop ground-breaking products or ser-
vices until 2020. The different phases of this program include
business innovation grants for feasibility assessment pur-
poses (Phase I), business grants for innovation development
and demonstration purposes (Phase II), and support services
to facilitate access to risk finance for commercial exploitation
(Phase III). Future and Emerging Technologies (FET) program
is another collaborative funding opportunity under Horizon3646 | Lab Chip, 2015, 15, 3638–36602020.83 FET-Open funds breakthrough and early ideas with
minimum three project partners from EU countries. This ini-
tiative provides up to €4m financial support to any potential
technologies without topical scope restrictions. Recently,
European Investment Bank Group and the European Com-
mission under Horizon 2020 launched InnovFin – EU
Finance for Innovators.84 This program consists of integrated
and complementary financing tools and advisory services that
cover the entire value chain of research and innovation for
SME and large organizations. The funding is available to EU
as well as countries in the vicinity of Europe. By 2020,
InnovFin will offer €24b of debt and equity financing.
Competitiveness of Enterprises and Small and Medium-
sized Enterprises (COSME) is another EU program that offers
€2.3b until 2020. COSME support SMEs to (i) access equity
investment and loan funds, (ii) improve access to markets,
(iii) create framework conditions for the competitiveness and
sustainability of Union enterprises, and (iv) promote entre-
preneurial culture by creating favorable conditions for busi-
ness formation and growth. COSME facilitates startup
funding through the Loan Guarantee Facility (LGF) and the
Equity Facility for Growth. Through COSME LGF, European
Investment Fund offers direct and counter guarantees for
financial intermediaries such as banks and leasing compa-
nies to provide an incentive loan and lease finance to
SMEs.85 While the direct guarantee is issued by the bank to
the beneficiary, a counter guarantee involves the bank
requesting a foreign bank to issue a guarantee on their
behalf. In case of invocation of the bank guarantee, a counter
guarantee ensures that the customer is liable for any
expenses for attorney, interests on delayed payment, taxes
and other levies. COSME guarantees allow SMEs, which can-
not access the traditional banking system, to obtain to debt
finance. Additionally, the LGF includes securitization of SME
debt finance portfolios. Since 2007, over 240 000 SMEs have
benefitted from this initiative in the European Union and
affiliated countries. The second part of the COSME is the
Equity Facility for Growth, which invests in funds that offer
venture capital and mezzanine finance for expansion and
growth. These funds are distributed based on the commercial
potential of the product and growth potential of the startup.
This program has funded €2.3b in equity investments since
2007.85
Additionally, Eurostars is another program that supports
high-tech small and medium enterprises, which develop
innovative products, processes and services.86 This program
has a budget of €1.14b until 2020, and it provides funding
for transnational innovation projects that can be rapidly com-
mercialized. Eurostars is supported by €861m of national
funds from its member countries and is further funded by
€287m from the EU, so the funding decisions are made on a
country-by-country basis. In the Eurostars program, the par-
ticipants have partners from two or more Eurostar countries.
The participants of the program are in 34 EUREKA countries
(e.g., Russia, South Korea, Canada and South Africa), and the
European Union.This journal is © The Royal Society of Chemistry 2015
Table 4 Regional dependence of entrepreneurial condition
Regional condition Factors
Access to finance The availability of resources covering equity, grants, subsidies, and debts for small and medium
companies
National policies and government
programs
Regulations, taxation, and direct assistance applied to the emerging companies
Entrepreneurship education The training for entrepreneurship starting from high school
R&D transfer The penetration speed of R&D to the commercial opportunities
Commercial and legal infrastructure The presence of legal and commercial services promoting small and medium companies
Market regulations The dynamics and openness of markets for startups
Physical infrastructure Smooth access to land, space, utilities, transportation at competitive prices for enterprises
Cultural and social norms The acceptance of startup activities in society and culture
Lab on a Chip Critical review
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View Article OnlineSMEs have access to the Enterprise Europe Network that
covers 600 member organizations and more than 50 member
countries for creating businesses in the EU. This European
network supports SMEs to determine financing strategies,
find international business partners, and obtain advices for
diverse issues including EU laws and standards.3.3. Financing for Global Entrepreneurship
Entrepreneurship dynamics are linked to the unique ecosys-
tems that differ across different regions of the world (Table 4).
These ecosystems are composed of conditions that influence
the business creation and growth.87 Entrepreneurial condi-
tions are mainly shaped by conditions in different regions
(Fig. 5).88 For example, business regulations may improve the
business opportunities, or hinder the business plans. Eco-
nomically developed countries such as North America and
Europe provide improved financing options and infrastruc-
ture as compared to other developing regions such as
Africa.89 On the other hand, national policies and govern-
ment regulations in Africa are as supportive as the developed
countries. Interestingly, one common problem is that the
entrepreneurship education at schools is low in almost every
part of the world, necessitating new policies that can enhance
the self-motivation of students for promoting personal initia-
tives.88,90 In comparing North America and Europe,This journal is © The Royal Society of Chemistry 2015
Fig. 5 Entrepreneurship indicators or conditions that influence the creationregulations and policies are more supportive in Europe, while
the financial sources, physical infrastructure, and cultural
values weigh stronger in North America.88,90 From the per-
spective of VC investments, United States alone brings higher
capital to the new companies as compared to Europe.90 How-
ever, only a small portion of new startups receive VC funding.
Therefore, other informal funds from various resources play
an important role as the backbone of financial operations in
all countries. Under the light of these regional analyses that
span a wide range of entrepreneurial parameters, co-founders
should carefully decide on their commercialization and
funding strategies.4. Marketing and sales strategies
Marketing high-tech products is fundamentally different than
traditional industries due to: (i) higher R&D investments, (ii)
increased uncertainties, and (iii) intense competition for new
products.91–93 Small- and medium- size high-tech enterprises
with high-profit potential (e.g., biotechnology) have high
risks.94 Such companies should not only create value, but
also capture the created value.95 This ability depends on the
company's capability in creating and sustaining competitive
advantages.96 Positional advantage in the market is an impor-
tant stream of the competitive edge.96–98 The brand nameLab Chip, 2015, 15, 3638–3660 | 3647
and growth of companies in different parts of the world.88,90
Lab on a ChipCritical review
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View Article Onlineand the status of the company are key factors in maintaining
the competitive advantage.99 When the product life cycle is
short, market awareness and competitor analysis are critical
in maintaining the positional advantage.100
The company can position itself in differentiator/innova-
tor or cost leadership strategies. The cost leadership strategy
is unrealistic for startups and early-stage companies since
this approach requires increasing economies of scale and
achieving high-volume advantage through promotion and
price subsidization.101 This requires startups to innovate and
exploit first-mover advantages. For example, Bioanalyzer
(Agilent Technologies) was launched in 1999 to provide
sizing, quantitation and quality control of DNA, RNA, pro-
teins, and cells on a chip.102 The device as an early mover to
the field had a successful product lunch. There are several
reasons why innovator strategy is more advantageous than
cost leadership strategy. The first reason is that new products
have low demand, which does not require large production
capabilities. Second, this strategy allows shifting to new tech-
nologies faster at lower costs compared to large compa-
nies.103 The innovator strategy requires wide market aware-
ness, which is the market's familiarity with the company
name, reputation, brand, and the products.100 However, mar-
ket awareness may not be directly related to the profit
increases.104
In high-tech industries, hardware is constantly upgraded
producing obsolete products, and the customers have limited
time to understand the benefits of a new product. Marketing
a high-tech product requires understanding the customers.
Ideally, several factors such as customer base, the purchase
decision, and its timing should be identified. Customer pur-
chase decisions are based on the rate of technology adoption,
categories of adopters, and the chasm. The rate of technology
adoption is based on the benefits for the customer. Hence,
the businesses should analyze customer perceptions of bene-
fits compared to costs. Another factor in marketing high-tech
products is compatibility. Customers seek similarity to
existing user interfaces as the learning curve is a challenge
and commitment for the customer. Another consideration is
the complexity and compatibility with other products, for
example, a device that operates through USB and does not
require coding is a convenience for the customer. For exam-
ple, MinION (Oxford Nanopore Technologies) in a handheld
DNA sequencing device that operates through USB. The use
of the product should be simplified to the most basic level at
the least sample preparation or initial operation steps. For
instance, i-STAT (Abbott) and the LABGEO PT10 (Samsung)
require an unprocessed drop of blood to operate. If this can-
not be achieved due to complexity, the businesses should
offer training and education in using the product through
online training programs or on campus demonstrations.
Additionally, observability also plays a role in the rate of
adoption. This factor involves the consumer's ability to assess
the benefits and may be independent of the seller's market-
ing approach. The factors listed are hurdles to overcome in
achieving effective marketing. Hence, businesses should3648 | Lab Chip, 2015, 15, 3638–3660arrange their marketing strategies to offer compelling rea-
sons for overcoming customer's uncertainty and skepticism.
Traditional marketing strategies assume that the customers
understand the usefulness of the products and know how to
evaluate them. However, the businesses should educate the
potential customers to reduce the barriers in purchasing
decisions.
Marketing and sales are two distinct processes that are
closely intertwined and work together to increase company
revenue. While large firms may have employees handling
marketing or sales in different departments that work in par-
allel, startups do not have the finances to hire specialized
employees and often fail to differentiate between the two.
Both marketing and sales are necessary for the success of a
business, and strategically combining efforts on both fronts
will lead to substantial business growth. Marketing targets
large groups or the general public while sales focuses on
smaller groups or individuals. Furthermore, marketing cre-
ates sales opportunities based on customer values. On the
other hand, sales converts consumer demand to match the
product. Marketing involves identifying a customer base,
developing products for meeting meet the demand, creating
a general awareness about the product, and building a brand
for the product to generate leads or prospects. To raise aware-
ness about the product, marketing may consist of advertis-
ing, social media campaigns, public relations (PR), and
online marketing. At the heart of the high-tech marketing is
the ability to communicate the benefits of the product to cus-
tomers. This involves the ease and clarity of communicating
the incentives to own the new product to the prospective cus-
tomers in terms that the consumers understand. The termi-
nology and the message should be carefully selected to com-
municate an engineering concept to biologists, medical
professionals, and purchasing staff in academia and indus-
try. The ultimate success of a marketing plan requires
researching the prospective customer base, specifying the
consumer demographics and demand, and utilizing targeted
marketing messages.
While marketing is typically indirect and acts at a distance
through the media, sales is human driven and consists of
direct interpersonal interactions. Sales converts the prospects
obtained by marketing into purchases. Thus, sales operates
on much shorter timescales that involve finding a target cus-
tomer, building a relationship through interpersonal interac-
tions including one-on-one meetings, networking, emails,
and phone calls, and converting the potential customer into
a paying a customer. The success of the sales plan is driven
by the quality of the salespeople in terms of their experi-
ences, training, skill sets, and personal contacts. Therefore,
startups should hire the salesperson with the right relation-
ships for the target market.
Most high-tech products and lab-on-a-chip devices are in
the development state or in an early stage of their product
cycle. Hence, they are targeted toward business-to-business
(B2B) transactions, including universities, research institu-
tions, and companies. The majority of B2B companies areThis journal is © The Royal Society of Chemistry 2015
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View Article Onlinedriven by sales as opposed to marketing. In products targeted
to B2B transactions, the sales volumes are low as compared
to business-to-customer (B2C) transactions. The smaller cus-
tomer base is typically comprised of committees of buyers
who are more easily accessible through sales teams. The buy-
ing committee has a rigorous decision-making process that
involves the assessment of technical aspects of the product
or the service and the inspection of the device to reduce the
risk of buying a frivolous product. Therefore, these interac-
tions are usually relationship driven and stem from face-to-
face interactions. Since the transaction size of the sale is typi-
cally larger in B2B companies, the building of trust during
these meetings plays an important role. In B2B transactions,
buyers are often experienced and understand the benefits of
the product in terms of cost and specifications. The buyers
are also well aware of the technology trends and the range of
competitive products in the market. On the other hand, most
B2C companies are driven by marketing to reach the masses.
Since media is an effective way to advertise to potential cus-
tomers, early stage marketing tactics involve the use of the
internet. ESI† describes early stage marketing tactics.
Jessica Livingston, a partner at startup accelerator Y
Combinator, advises startups to focus their efforts on sales
rather than marketing.105 Specifically, startups are advised to
seek out a core group of early adopters that should be
involved in the development of the product to ensure that
the product meets consumer needs; once the technology
becomes an extended product, these early adopters should be
the focus of sales. The early adopters often collaborate and
communicate across industry boundaries, and allow spread-
ing the presence of the product horizontally.106 Additionally,
sales should target key influencers in the market, including
brands, bloggers, and reporters.
Startups are under financial constraints, and this necessi-
tates the use cost-effective marketing tactics. The co-founders
should define success using a metric with a direct correlation
to company growth, such as number of new users or a certain
revenue each month and ensure that everyone on the team is
working toward this metric. Then, the team should set a bud-
get and focus resources toward avenues that have proven suc-
cessful historically in the target market or with competitors.
A variety of tactics should first be tested with smaller bud-
gets. Those that contribute to company growth should then
be allocated a larger portion of the budget.
The marketing of new high-tech products is an important
aspect of commercialization strategy. While it is important to
generate revenues, the resources should be directed to having
a market focus. High-tech equipment requires learning costs
on the end user and generally adopted to use for a long time.
Hence, this requires the customers to get used to the technol-
ogy and recover the investment in the high-tech product.
Therefore, rapid introduction of improved versions of a
device or service can make the customer regret the purchase
and delay the new purchases. Hence, it is in the interests of
the company to introduce the new products in a timely man-
ner and avoid excessive pace of product development.This journal is © The Royal Society of Chemistry 20155. Exit strategies
An exit strategy allows the business owners to decrease or
eliminate their equity in the company to recover the initial
investment with/out return.107 The sooner the management
team plans for the exit, the more rewarding the exit is likely
to be. Additionally, preparing an exit takes time, and these
options require forethought and preparation. Hence, the
management should consider the end goals and strategize
the exit plan to maximize the benefit for stakeholders and
employees. Assessing the market condition is also critical in
determining the exit strategy. For example, the demand for
the products of the company, acquisitions between investors,
and the presence of strategic buyers affect the exit strategy.
Hence, the inventors should engage with private equity part-
ners, commercial lenders, investment bankers and financial
professionals to assess the trends in the market. The range of
exit strategies includes acquisition/merger, taking the com-
pany through an IPO, management buyout, and turning the
company into a lifestyle business. In addition to the main
exit strategies, dual-track approaches should be also consid-
ered. For example, marketing the company to both investors
and potential strategic buyers can be pursued to capitalize
the most attractive exit strategy. While the public market
investors are interested in the business as a whole and the
prospects for growth, the strategic buyers might want to
assess specific aspects of the company.
The owner sells the company to another business by nego-
tiating the price, which involves the seller to pay in cash,
stock, or a combination. The owner should choose a strategic
fit, which will allow the buyer to expand into a new market,
and offer a new product to their existing customers. Such
customers might include companies that require critical
capabilities that are more costly or take longer if they devel-
oped themselves. One issue with this approach is that the
acquired management might be locked up into working for
the combined company, which might let them go at some
stage. The buyer might not retain the management team, or
make substantial changes in the company's operations, staff,
and business lines. The seller should make the company
appealing to the acquisition candidates by developing the
compatible products that they match with the prospective
suitor's products and fit into product portfolio. For example,
Solexa Inc. (Hayward, CA), a spinoff from the University of
Cambridge, developed a single molecule sequencing plat-
form, which was compatible with Illumina's DNA colony
sequencing technology.108,109 In 2006, Solexa was acquired by
Illumina for $650m in a stock-for stock merger to comple-
ment its genotyping and gene expression platforms.110 In
acquisitions, the liquidity is quite high due to the sale of all
or the most of the stock. At the end of the sale, the seller is
likely to lose the control of the management. One disadvan-
tage of this approach is that if the prospective buyer is no
longer interested in the company, the company might end up
with a specialized product. In summary, this approach might
allow the seller to make more money than other approachesLab Chip, 2015, 15, 3638–3660 | 3649
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View Article Onlineif multiple bidders are involved. Another key to sell a busi-
ness involves analyzing the capability of the competitors or
the buyers to develop the technology internally and under-
stand their patent position. Hence, the seller should set a
realistic price to sell the business at a peak price.
A merger is similar to an acquisition although the main
goal is to bring together two companies (rather than one
company acquiring the other) to obtain a strategic market
position or obtain a customer base and create rapid growth
or expand to new markets. The difference between a merger
and acquisition is that a merger consists of consolidation of
two companies into a single entity, whereas acquisition
involves a larger company to take over another company,
which may result in the smaller company to dissolve or oper-
ate under the parent company.
The initial public offering is rare, rigorous, and one of the
most attractive exit strategies. It involves selling a portion of
the company in public markets. This approach allows the
management and the investors to remain in place and oper-
ate the company. If the company is funded by investors with
a track record of taking companies to public, the company
has higher chances. Additionally, the IPO exit is correlated
with the total amount of venture financing and company
total sales.111 However, after the IPO, the company is subject
to regulations such as Sarbanes-Oxley requirements, while
the performance of the company is scrutinized by institu-
tional investors and financial analysts.112,113 Case study 4
about RainDance Technologies, Inc. describes a microfluidics
company that positioned itself in the genomics market to be
profitable and filed for IPO.
The management buyout approach involves recapitalizing
and selling the business to the next generation of managers
or employees. In this case, the seller finances the sale and
allows the buyer pay it off over time. The buyer can finance
the transaction through a combination of private equity and/
or debt collateralized by the company's assets. One approach
is a low-money-down deal, which allows the owner to earn
more money than closing. This approach results in immedi-
ate liquidity to the seller and shareholders while allowing the
company to stay as a private enterprise. An advantage of this
approach is that the buyer is likely to preserve the business
values, and the transition is smoother.
The lifestyle company approach involves reducing the
equities of the company by increasing the personnel salaries
regardless of the performance of the company. The activities
of the company are kept at minimum, but the shareholders
remove a comfortable share from the equities. However, tak-
ing out too much money can hurt the company in the long
term, and upset investors. Additionally, the way the money
pulled out might have negative tax implications. For instance,
a high salary is taxed as ordinary income; however, an acqui-
sition can bring money in capital gains.
The reason that a startup company is founded typically
influences the exit strategy, and it depends on the objectives
of the people who run the business. Nevertheless, as the
stock of the owners is diluted by the angel investors and3650 | Lab Chip, 2015, 15, 3638–3660venture capitalists, all the shareholders must reach a consen-
sus to plan an exit strategy. One important consideration is
that the inventor must decide whether s/he wants to manage
the business. For example, in management buyouts and
IPOs, the original team might play the same roles after the
transaction; however, in a strategic acquisition, the new
owner might replace the management team with its own
employees. Hence, strategic acquisition is a good option for
the companies struggling with succession-planning issues
while management buyouts and IPOs are preferred when the
teams want to stay in control of the business. Another signifi-
cant consideration in choosing an exit strategy is the evalua-
tion of the liquidity needs. For example, while a strategic
acquisition often generates an immediate cash payment, IPO
is likely to result in a share lock-up agreement, which does
not allow selling the shares for up to six months. Addition-
ally, in management buyouts, the seller may receive the
liquidity over time. Furthermore, since all shareholders must
agree upon the exit strategy, the entrepreneurs should look
for partners that will not pressure to sell the company soon,
and allow making a decision on the right exit strategy over
time. The company's future potential should also be consid-
ered before making a decision about the exit strategy. For
example, the shareholders might not require immediate
liquidity and consider the company's future growth potential.
Hence, this influences the exit strategy, which might allow
the seller to retain an ownership interest. For example, IPO
allows keeping a substantial interest in the business. This
also applies to the management buyout, which allows for par-
ticipating in the growth of the company. On the other hand,
an acquisition will generally greatly reduce and eliminate the
sellers influence in the future direction and performance of
the business. Another consideration in IPO strategy is the
Sarbanes-Oxley agreement, which is bureaucratic and costly
process to protect investors from corporate accounting
fraud.112,113 In preparation for an IPO, these steps are taken
early on, which involves forming an independent board,
arranging an independent audit, and modifying the reports
to meet required standards.
While liquidation is not necessarily an exit strategy but
rather a terminal endpoint, it is a common end of many
startup companies. This process requires a company to cease
operations, sell the assets and redistribute the proceeds to
creditors, employees, and shareholders according to priority
of claims. Any proceeds from the assets must be paid to the
creditors first; however, the shareholders are always paid last.
In the long term, liquidation might jeopardize the client list,
reputation of the entrepreneur and the business relation-
ships. A company goes out of business by ceasing operations
and liquidating its assets. After the liquidation, creditors are
given priority to recover their investments. However, if the
company does not have assets, it can file for bankruptcy to
avoid further harm by lawsuits that try to collect the debt
from the corporation. The creditors may sue the officers as
well as the corporation, and the defendants have to appear in
court. Not appearing in a lawsuit results in a judgmentThis journal is © The Royal Society of Chemistry 2015
Fig. 6 Reasons of startup failures. Adopted from ref. 116. CB Insights.
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View Article Onlineagainst the defendant with consequences such as liabilities.
Bankruptcy is a slow and inexact legal action that allows a
company or individual to pay the debt to creditors by liquida-
tion according to priorities in the Bankruptcy Code. There is
clear guideline whether a failed business should file a liqui-
dation (Chapter 7) or rehabilitation (Chapter 11) proceeding;
however, this decision is based on the value and type of the
assets, creditors, and the management team to oversee the
bankruptcy process.114 In contrast to the direct liquidation
in Chapter 7, Chapter 11 (corporate bankruptcy) involves
restructuring the company and continue to operate while
paying debts. Chapter 11 preserve assets better, and it
allows creditors to recover more money as compared to
Chapter 7.115
Filing bankruptcy may protect assets from creditor action
and preserve value for the payment of the taxes. In bank-
ruptcy, the court appoints an official who administers the
debtor's bankruptcy estate. The trustee is responsible for the
liquidation of the assets, returning equipment, managing the
creditors, and allowing the management to leave the com-
pany. Under the Bankruptcy Code, the trustee can sell the
leases to recover value for the creditors, which is not possible
outside bankruptcy.114 Furthermore, automatic stay prevents
creditors from diverting cash, which otherwise might be used
for paying taxes, salaries, and guaranteed debts. The bank-
ruptcy has advantages over liquidation such as obtaining
increased value for the assets. It also maximizes the recovery
and the exposure of management or investors can be limited
by addressing debts. Furthermore, the assets can be sold to
insiders in fair prices. There are also downsides filing a bank-
ruptcy. For example, bankruptcy may prevent the manage-
ment to move to a new position in another company due to
the reputation that follows, and may also increase the likeli-
hood that a creditor sues individuals.
6. Reasons for startup failures
The number one reason for startup company failure is the
lack of market for the product (42%).116 To overcome this
challenge, entrepreneurs should focus on the customer
development simultaneously during product development to
addresses a niche market. Fig. 6 lists other reasons for fail-
ure, including lack of sufficient capital (29%) and an incom-
petent team (23%).116 Furthermore, premature scaling has
been cited as another significant reason of startup failure.117
When the initial commercialization strategy does not work,
the ability to pivot to a different strategy is key to the success
of a startup.
6.1. No market need
A primary reason for the lack of translation of technology to
a product is the absence of a true market need. For example,
a range of proof-of-concept device exists in the microfluidic
literature, though the field suffers from the lack of commer-
cially successful products.28 Disruptive technologies may lead
to products with benefits that are not obvious in the shortThis journal is © The Royal Society of Chemistry 2015term. Marketing these high-technology disruptive innovations
requires companies to adopt strategies that may seem coun-
terintuitive as compared to those associated with the market-
ing of a sustaining innovation.118 For example, microfluidic
laboratory assays have long term benefits of reduced volume
of samples and rapid analyses. However, benchtop instru-
ments are capable of performing equivalent assays, and
hence laboratories are unwilling to shift to new products
unless there is a compelling advantage. Such high-tech prod-
ucts have a limited customer base in the short term. There-
fore, established enterprises may not enter into a licensing
agreement, and a startup may not have sufficient funds to
sustain a delayed entry into the market. Additionally, the
startup may need a longer period of time to validate their tar-
get market than the founders initially expected. This underes-
timation could lead to scaling up prematurely and ultimately
lead to the company's demise. Thus, entrepreneurs should
avoid investing into scalability of the product before the
product is fully developed. Similarly, companies that have
acquired customers should not immediately act on feedback
or scale in response to their initial success before validating
the market size.
Rather than attempting to find a market for their existing
product, entrepreneurs should consider an immediate mar-
ket need when developing their technology. Market-driven
startups have strong and consistent growth, whereas product-
driven startups eventually reach a point of slow or stalled
growth since they do not have the capability to respond to
the dynamics of the marketplace. Products that solve a previ-
ously unanswered question and target a niche market have a
greater chance of successful commercialization, while frivo-
lous products will often not advance beyond the innovator
technologist customer base (Fig. 7). ESI† describes Roger's
diffusion of innovations theory for high-tech products. Less
served markets segments have higher penetrability, but offer
lower industry prestige. While many startups focus theirLab Chip, 2015, 15, 3638–3660 | 3651
Fig. 7 Roger's diffusion of innovations theory.
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View Article Onlineresources to entering saturated markets, this may not be the
correct strategy in the markets dominated by leading compa-
nies. When entering the niche markets, the startups need to
question the reasons a similar product does not exist, check
their assumptions, and evaluate whether there is a market
demand for their product.
Understanding the competitor's performance and the cur-
rent state of the target market is necessary to build a sustain-
able business. If a product is ahead of the market, it will not
be successful because the customers are not yet ready for this
particular technology. Entrepreneurs should also be able to
predict trends to ensure that the market for their product will
still exist in the near future. Even if the product is designed
with the market in mind, the initial prototype may not satisfy
the market need, and the product needs to undergo a num-
ber of iterations to fit the product to the market. This itera-
tive process forms the basis for the concept of the lean
startup model.119 The lean startup is a validated learning
approach that measures and shortens product development
cycles by obtaining customer feedback. The concept of vali-
dated learning involves implementing an initial idea and
quantitatively measuring its effect. This process is followed
by a series of iterations until metrics indicate that a specific
goal is achieved. Sometimes the product needs to be re-
designed completely, indicating that the team did not suc-
cessfully validate the ideas with customers during the devel-
opment phase.
The products need to be marketable toward the end user.
A common failure of high-technology entrepreneurship is
that the innovators often neglect the process of producti-
zation. Even if entrepreneurs develop a new technology that
has a market need, it will not be commercializable if it is not
an extended product that is easily adaptable by the customer.
For example, a lab-on-a-chip device should be able to stand
alone or be compatible with existing equipment, require no3652 | Lab Chip, 2015, 15, 3638–3660expertise in lab-on-a-chip systems to operate, and offer a sub-
stantial advantage rather than an incremental improvement
on comparable products. Additionally, the product should be
as simple as possible without losing functionality. A common
pitfall is for teams of technical founders to overengineer their
technologies. However, adding “nice to have” features that
do not improve the core value delay the product launch and
shrink the time that is needed for building a customer base.
While determining the specific target market, it is impor-
tant at the design stage to consider the composition of the
target customer base. For example, the customer base of a
next generation sequencing library preparation system con-
sists primarily of research institutions and biotechnology
companies; however, point-of-care diagnostic devices such as
the i-STAT system (Abbott Laboratories) are marketed toward
hospitals. It is also crucial to determine who would pay for
the product. In the case of the diagnostic device, the cost of
the supplies necessary to run the assays could be absorbed
by the hospital, the patient, or paid through medical reim-
bursements. The market size and available funds must be
sufficient to counteract the costs associated with launching
the startup. Before attempting to sell a product or service, the
entrepreneurs should run a competitive analysis of the indus-
try, and realistically determine the company's offerings. This
may require collecting constructive, objective criticism from
potential customers. To ensure the marketability of the prod-
uct, entrepreneurs should create surveys and alpha test
groups to gather information about their customers and the
factors that affected their prior purchasing decisions.
Although alpha tests are predictive, they do not guarantee the
eventual market penetration. The product should have a com-
pelling value proposition to cause the customer to commit to
purchasing.
Most entrepreneurs are overoptimistic about marketing
deadlines and acquiring customers. It takes more than hav-
ing a website, product or service to acquire customers. The
promotion of the product should begin before the product is
finalized. For example, the development status of the product
can be discussed in the media and blogs to promote the tech-
nology for obtaining early reviews and create enthusiasm
about the product. The company's website may even include
a form for preorders. Hence, the marketing plan should be
implemented at least three months before the launch date.
Furthermore, the lifetime value of a customer should be
higher than the cost of acquiring the customer. This means
that the company should be able to acquire customers for
less money than they will generate in value of the lifetime of
company-customer relationship. Hence, it is often important
to develop commercialization strategies that allow scalability
to acquire and monetize customers and at a higher degree
than the cost of acquisition.6.2. Lack of sufficient capital
Another main reason that startups fail is that they exhaust all
working capital and cash reserves.120 Only 4% of companiesThis journal is © The Royal Society of Chemistry 2015
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View Article Onlinereach more than $1m in revenue, and 0.4% of all businesses
achieve $10m in revenue.121 The funding requirements
should be planned at early stages in the startup to gain key
infrastructure and maintain a cash flow for day-to-day opera-
tions. Venture capitalists are more likely to invest in a com-
pany that has already raised initial seed funds. The Director
of Technology Licensing at MIT, Lita Nelsen, stated that one
of the largest barriers in the commercialization of academic
research is to getting investors to take the risk in an
undeveloped and unproven technology.
Entrepreneurs should meet with potential venture capital-
ists and angel investors at the early stage of product optimi-
zation to evaluate initial financial performance. During these
interactions, investors look for three main qualities in a
startup team to decide on a long-term commitment of
funding. Investors want to see the developmental and finan-
cial progress of the company. Founders should be able to
show the evolution of their success in business with suffi-
cient initial capital that can at least cover the liabilities.
These records will prove whether the company has achieved
steady growth over time or not. To create even faster momen-
tum, these startups should also setup network of alliances
with established companies to access resources including
knowledge transfer and shared equipment use.122 Based on
this network, investors will feel more confident in
approaching a startup for funding opportunities.
Investors are mostly interested in strategic business plans
that can impact large target markets.123 The entrepreneurs
should quantify the impact of their visionary products in
terms of measurable metrics. They will then need to come up
with a unique business model that converts concepts to a
profitable product. Instead of changing the business model
several times throughout the development, companies may
focus on a “killer” product124 or a platform technology using
an effective business model.125 Besides focusing on their own
vision, the entrepreneurs should avoid losing perspective,
and they should seek feedback from venture capital firms
and validate their commercialization strategy. However, not
all companies are required to have a killer application, but
can be based on generic products. For example, microfluidic
ChipShop GmbH (Jena, Germany), founded by Claudia
Gärtner and Holger Becker in 2002, provides generic and
bespoke lab-on-a-chip devices, and services for manufactur-
ing, standardization, and product development.
A primary reason that startups lack sufficient funds and
are unable to raise more is that the next milestone was not
achieved before the company ran out of cash. The manage-
ment team should be cognizant of how much cash is avail-
able and whether the funds are sufficient to realize the next
milestone. Additionally, the management team needs to rec-
ognize when to conserve funds and increase spending for
financial benefits. The valuation of a startup does not scale
linearly with time. At the early stages of product develop-
ment, management should reduce operating costs and elimi-
nate unnecessary spending. A common mistake is to hire
extensive marketing and sales staff when the product is stillThis journal is © The Royal Society of Chemistry 2015incomplete and does not meet the market need. An addi-
tional financial consideration is being cautious about the
expansion of operations after initial success if the business
model is not validated. Furthermore, expansion to new and
bigger office spaces in upmarket city locations is costly and
can have significant impact on the budget. Extension of the
business into locations that stretches the logistic capabilities
can dramatically increase overhead expenditure. While the
funds should be spent conservatively during the initial stages
of the startup, once the business model is proven, and the
current state of the market and customer base are well-under-
stood, it is necessary to invest a significant amount of capital
to reach the milestones and increase the valuation of the
company. Case study 5 about Smart Holograms Ltd. presents
a biosensor/security company that expanded before proving
its business plan resulting in its eventual demise.
Financial management provides a set of tools and tech-
niques that enable the business to control and manage
money. Monthly financial reports and management accounts
should be prepared, and entrepreneurs should be well versed
in financial jargon. During the early stages of the company,
the management team can utilize an accounting package to
track finances. As the startup grows, and more money is
available, they can then consider employing a part-time
book-keeper followed by a full-time accountant.6.3. Incompetent team
The third leading reason why startups fail is due to incompe-
tent management. Poor teams are often weak in strategic
areas of company development. For instance, they may build
a product that does not meet the market need while carrying
out a partially developed commercialization strategy. They
are typically limited in executing tasks, managing finances,
and remaining on schedule. Importantly, an incompetent
management builds weak teams, leading to the inevitable
failure of the company. A successful management team is
comprised of individuals who are passionate about the ven-
ture, motivated, organized, and interpersonally strong.
Investors look for experienced management teams that
have a strong track record in industry.126,127 Ideally, the man-
agement team should have experience in technology and
have background in the development and maturation of
startups.128 Such knowledge is required in project and per-
sonnel management, forming and implementing the mis-
sion/vision statements, and the execution of the commerciali-
zation strategy. Hence, hiring experienced management or
receiving mentoring can improve the chances of the company
to be successful. Additionally, startups should present biogra-
phies of team members in their pitch presentations to the
investors, creating the first convincing impression that the
company is based on experience and a sound scientific foun-
dation. It is desired to reach a balance between “friends” and
“big names” in the field. As part of the team, the structure of
the board of directors and their qualifications should also be
outlined. It is recommended to limit the term of theLab Chip, 2015, 15, 3638–3660 | 3653
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View Article Onlinemembers of the board of directors to keep the direction more
focused at early stages, and not allow any member to influ-
ence the company to make decisions for his/her personal
benefit. The governance principles of management should
also be clarified.
In addition to the entrepreneur and the chief scientific
officer, management teams should include a strategist, a tac-
tician, a financier, and consultants.126 The co-founders of
these companies should set out the vision of products that
address specific needs in the market. The strategist holds
research and marketing expertise, and should help position
the company into commercial partnerships considering the
competitive nature of the business. With a project manage-
ment background, the tactician should take care of the daily
operation principles of the company to meet the deadlines.
The tactician should also channel the product according to
the regulatory needs of the government and the Food and
Drug Administration (FDA). The financier should have experi-
ence in banking to help raise capital and aim to increase the
stock price for the company as early as possible. The team
should designate one person to be responsible for executing
the company's critical items of focus and ensure that the
company is on track to meet the next target milestone. The
management team needs to frequently evaluate the goals of
the company and the current progress toward reaching them
in addition to assessing the company's mission and vision.
Furthermore, the team should constantly question the mar-
ket need, the impact of the product, the position of the com-
petition, and the strategies toward securing a competitive
advantage and commercially successful product.
The startup requires individuals with diverse backgrounds
to provide a balanced point of view. For example, technical
founders are often motivated in creating interesting technolo-
gies that can improve their life styles. However, marketing
personnel are needed to ensure that the product is commer-
cially viable and meets the current market need. Balanced
teams with one technical founder and one business founder
raise 30% more funding, have 2.9× more user growth, and
are 19% less likely to scale prematurely than teams with
solely technical or business-heavy founding members.117
According to Steve Hogan, whose Silicon Valley-based
firm Tech-Rx is hired to assist failing startups, the most
common reason why companies fail is that they are founded
by sole first-time entrepreneurs.129 The sole founder has
many associated difficulties. The company may face issues
acquiring investments because a sole founder may be seen
as less trustworthy or lacking interpersonal skills. Addition-
ally, creating a startup is a difficult task that is too time-
consuming for one person to manage. Benefits of having co-
founders include having colleagues with different perspec-
tives to brainstorm ideas and troubleshoot problems. Co-
founders can also boost confidence and morale and provide
motivation at low points in the company. According to
Startup Genome Project, solo founders take 3.6× longer time
to reach scaling stage as compared to companies with two
founders. Similarly, solo founders are 2.3× less likely to3654 | Lab Chip, 2015, 15, 3638–3660pivot their commercialization strategy.117 However, it is
important to ensure that the co-founders are likeminded in
their entrepreneurial aspirations. The partner must be
completely committed to the startup, be able to give an
equal amount of time or money as the solo founder, and be
willing to take financial risks. It was found that successful
startups had founders who were driven by impact rather
than money or experience.117
Lastly, the importance of connections and mentorship
should not be underestimated. Each team member should
build their own network of influential connections. Connec-
tion to mentors, key influential users, industrial partners,
analysts, media outlets, and business alliances aid in market-
ing and play a role in the ultimate success of the business.
It was found that investors' assistance in the startup had lit-
tle or no effect on the company's operational performance.
However, having mentors have significantly influence a
company's performance and the ability to raise additional
funds. Management teams that have helpful mentors and
track metrics effectively raise 7× more money and have 3.5×
improved user growth.1176.4. Unable to pivot and overpivoting
The ability to pivot the business model until it is proven
according to Steve Blank's customer development model can
be useful to enter a rapidly expanding or changing market.130
Customer development is a systematic approach to under-
standing customer values, and it consists of four steps: (i)
customer discovery, (ii) customer validation, (iii) customer
creation, and (iv) company building. Co-founders should
pivot between the first two stages through a series of itera-
tions to find the right business model. These steps ensure
that end-user demand is created and the business is scalable
by measuring expected customer behavior against the current
market. Hence, customer development should be developed
in parallel to the product development.
It is imperative to be able to adapt to a backup plan or
new strategy to overcome unexpected challenges. When the
initial strategy fails, the management team should be able to
quickly pivot to different strategy. While the fundamental
technology cannot be changed, the team should shift their
application to prevent wasting time, resources, and money.
This rapid change requires the management leadership to
make quick and efficient decisions and clarify the vision of
the company. If this decision-making process leads to delay
in meeting the milestones on time and interruptions in oper-
ations, the startup will likely fail. Since investors expect rapid
returns on their investment, time is a valuable asset during
the initial phases of a startup company. Although the initial
choice of commercialization strategy does not define a
company's performance, generally pivoting to an alternative
strategy at a later stage can greatly affect the chances of the
business to successfully exit. Startups that pivot their com-
mercialization strategy once or twice can raise 2.5× more
money, have 3.6× improved user growth, and 52% are lessThis journal is © The Royal Society of Chemistry 2015
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View Article Onlinelikely to scale prematurely than startups that do not pivot or
pivot more than two times.117
7. Case studies
1. Microchips Biotech, Inc. (Lexington, MA) was founded in
1999 as a spinoff company from Robert Langer's laboratory
at MIT. The company develops implantable pharmacy-on-a-
chip devices that can wirelessly release drugs in a controlled
manner.131 Their technology holds immense potential as
pain-free, controllable drug delivery and biosensor technol-
ogy, in particular for those with chronic diseases such as dia-
betes and osteoporosis. For example, the development of
pharmacy-on-a-chip devices can significantly improve the
lives of diabetics, who have to prick their fingers and inject
insulin up to five times a day. The company received early
funding from Waltham-based Polaris Partners, and
Medtronic, and it raised about $75m in venture capital and
grant funding, and it has not had a product past the FDA
approval for medical devices or booked any revenue.132 In
2012, the company published its first trial results that
showed that their pharmacy-on-a-chip technology could
deliver 20 doses to patients suffering from osteoporosis.133
However, in the same year, the company shut down its
research facilities due to lack of funding. The number of
employees of MicroChips, which once reached 40, decreased
to two in 2013. Recently, the company received a $6.2m
funding from Bill and Melinda Gates foundation to develop
an implantable electronic birth control device. This funding
allowed the company to return to its financially stable status
and increase its employees to ten as of 2015, and the com-
pany recently hired its fifth CEO. After pivoting to the area of
contraceptive implants, the company aims to deliver its first
product by 2018.
2. Diagnostics for all (DFA) (Cambridge, MA) was spun out
from George Whitesides’ laboratory at Harvard University in
2007. DFA as a non-profit company aims to commercialize
paper-based microfluidic tests for applications in resource-
limited settings.134,135 DFA has a for-profit subsidiary called
Paper Diagnostics, which aims to partner with companies to
develop tests for use in developed countries. The proceeds
from Paper Diagnostics are invested back into the nonprofit
branch of DFA. Whitesides is of the opinion that non-profits
such as DFA are needed as large companies in the market
are unwilling to lower costs, so academics have taken this
issue to their own hands.136 DFA won Harvard Business
School Annual Business Plan Contest and MIT $100k Entre-
preneurship Competition in 2008. In the same year, DFA
received a 5-year grant from the Gates Foundation, as sub-
contractor for the development of a Critical Organ Function
Test for the liver. The company received funding over $10m
from British Government, USAID and the Defense Advanced
Research Projects Agency (DARPA) to expand it technology
portfolio to applications in HIV testing and environmental
monitoring, and diagnostics for the assessment of immunity
status against tetanus and measles to support vaccination.This journal is © The Royal Society of Chemistry 2015The company has conducted two field trials in Vietnam and
Kenya in 2012 and 2013, respectively. In 2014, DFA received
$1m from Massachusetts Life Sciences Center to fund the
development of an Ebola diagnostic test. DFA has pivoted
multiple times since its foundation due to the diversity of its
funding sources. The company has not materialized a prod-
uct as of May 2015; however, it represents a unique non-
profit model, where the results can make a positive impact in
the developing nations.
3. Optofluidics, Inc. (Philadelphia, PA), founded in 2011,
is a spinoff company from the group of David Erickson at
Cornell University. Optofluidics develops instrumentation for
analysis and manipulation of nanoparticles used in the life
and physical sciences. At the time of the formation of the
company, Erickson's group was primarily involved in
photonics and microfluidics. After the publication of a high-
impact article,137 they decided to commercialize the technol-
ogy that offered nanomanipulation capabilities. His team has
filed about 30 patents over the last 10 years through Center
for Technology Licensing (CTL) at Cornell. A portion of these
patents have been licensed by Optofluidics and subset of the
company's broader portfolio. The CTL also optimized their
claims and assisted Erickson's team to create commercializa-
tion and marketing strategies. At Cornell, faculty are allowed
to dedicate 20% of their time to external matters. This
allowed Erickson to spend this time on creating and
supporting the company. Its co-founders applied for a NSF
Small Business Innovation Research (SBIR) grant to obtain
seed funding for the company. The NSF SBIR program had
several matching programs for external funding that helped
them attract early stage private investors. This also allowed
the co-founders to maintain significant equity in the
company.
Since its establishment in 2011, Optofluidics has worked
with investors and development partners such as Bio-
Advance, the NSF, the Defense Advanced Research Projects
Agency, and the Ben Franklin Technology Partners. The
investors guided Optofluidics to sharpen their exit strategy,
in which the company targets to generate certain amount of
sales before exiting. The company's marketing approach is
directed to promoting the product and increasing the visibil-
ity of the business to larger corporations. In this process,
they constantly communicate with suppliers and strategic
partners. Erickson emphasized that the desire to start a com-
pany is an important characteristic of an entrepreneur. Hav-
ing a startup throws academics to the bottom of a business
hierarchy. He advises that having an entrepreneurship mind
should start early on in the academic career, and having con-
versations with other entrepreneurs, getting a sense of a
business model around the technology, building a customer
base, and understanding the exit strategy. In 2012,
Optofluidics received Philadelphia Life Sciences startup of
the year award.
4. RainDance Technologies, Inc. (Billerica, MA), was
founded in 2004 as a spinoff company from the group of
David Weitz at Harvard. RainDance develops solutions forLab Chip, 2015, 15, 3638–3660 | 3655
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View Article Onlinegenomic analyses and non-invasive biopsy applications.
RainDance's direct competitors are Agilent Technologies (A),
Illumina (ILMN), and Qiagen (QGEN). Their core technology
is based on microfluidic lab-on-a-chip devices and digital
droplets.138 The company holds about 175 patents in its pat-
ent portfolio, and approximately 400 patents from strategic
deals. Their Digital Droplet technology allows the analyses of
cell-based and cell-free biomarkers in cancer, infectious dis-
ease and inherited disorders. The company's main products
are the RainDrop® Digital PCR System, ThunderBolts™ Can-
cer Panel, which analyzes 50 gene sequences including tumor
suppressor genes and drug resistant targets, and Thunder-
Storm® Next-Generation Sequencing Content Enrichment
Systems, a high-throughput system for production scale labo-
ratories. Their customers include academic and translational
research institutions, cancer centers, bio-banks, commercial
laboratories, pharmaceutical and biotechnology companies,
agricultural and industrial companies, and government
institutions.
In its first six years, the company focused on its core tech-
nology and developing its capabilities while demonstrating
over 40 different capabilities in proteomics and genomics,
particularly in single cell applications. At this stage, the com-
pany built a strategic partnership with Sanofi to apply their
core technology to drug screening and began establishing a
customer base. In 2010, company's board of directors
appointed S. Roopom Banerjee as the President and CEO.
Banerjee's first task was to set a clear vision, reorganize the
management and scientific teams, and identify a customer
base. His efforts focused on strategic partnerships that
enabled RainDance to move beyond technology development
and into the commercialization of its products. On the basis
of market trends and growing healthcare needs, RainDance
targeted a number of applications for automated testing of
biomarkers in cancer research. The commercialization strat-
egy of RainDance targeted the research community by creat-
ing open source cross-platform chemistries and establishing
compatibility with existing digital PCR and next generation
sequencing technologies, a rapidly developing field in which
$10b has been invested over the past decade.
To attract investment, the management team pitched the
unique attributes of their core technology, the qualifications
of their scientific team, and the opportunity in the market.
They also emphasized the strategic position of RainDance
with quantitative data from their own research as well as
published journal and conference articles by their early cus-
tomers. To attract further investment, they established a sub-
stantive value proposition by showing long-term ability to
supply innovative products. Since its foundation, RainDance
raised $125m from equities sales, and $20m in proceeds
from debt facilities and investors. It received $20m in its
Series E equity financing in April 2013, and in September
2013 Capital Royalty Partners invested $35m to support com-
mercial expansion of RainDance's product portfolio.139
RainDance filed for a $60m IPO on May 12, 2014, and its
revenues increased 78% to $30.6m from $17.2m in3656 | Lab Chip, 2015, 15, 3638–36602013.140–142 In addition to its success in financing,
RainDance initially executed an innovator marketing strat-
egy with a unique market position but adopted a cost lead-
ership strategy as their sales started growing. RainDance
also deployed an aggressive direct sales team that engaged
with customers, and their supply chain was supported by
distributors worldwide.
Banerjee indicated that the hardest challenge to commer-
cialization is the transformation from a technology into a
fully-functioning product. To maintain the company's posi-
tion in the market, the management team should optimize
their patent portfolio and build strategic partnerships to
expand within the vertical and horizontal markets. Banerjee
believes that the successful exit of a company depends on
three main factors: (i) employing a management team that
can move from vision to execution, (ii) strategically building
a team by hiring top talent, and (iii) successfully managing
its finances. In his opinion, entrepreneurs should assess the
performance of their company and always be willing to
upgrade their team constantly. Hence, this requires the abil-
ity to evolve the business and make quick decisions to meet
the product delivery milestones.
5. Smart Holograms Ltd. (Cambridge, UK) was a spinoff
company, founded in 2001, from Christopher R. Lowe's labo-
ratory from the University of Cambridge. The company aimed
to commercialize its holographic sensing technology com-
bined with microfluidic devices for applications in point-of-
care diagnostics, environmental monitoring, and security
(brand protection and product verification). The company's
technology was based on an equipment-free holographic
sensing platform, which consisted of diffraction grating
embedded functionalized hydrogels.143–150 As the hydrogels
swell and shrink in response to an analyte, the wavelength of
the diffracted light is correlated with the concentration.151–155
Based on its holographic platform, the company developed
its Verify-EYE technology for the counter (OTC) pharmaceuti-
cals, food, and cosmetics. The company also aimed at devel-
oping glucose-sensitive catheters for monitoring the concen-
tration of glucose in blood in real time. The company
received a proof-of-concept grant of £25k from the University
of Cambridge to assess the feasibility of creating a new tech-
nology, and further received funds from the university's Chal-
lenge Fund (£250k), the Small Business Research Initiative
operated by the Biological Biotechnology and Biological
Sciences Research Council (£216k), a contract from a leading
pharmaceutical company (£400k), and venture-capital
funding from Portion Capital (£5m).156 In 2008, Smart Holo-
grams employed over 40 personnel in the UK, held 40 filed/
granted patents and seven filed trademarks, and signed co-
development deals with blue-chip industry leaders. However,
the rapid expansion of the company before identifying a mar-
ket segment resulted in the depletion of its financial
resources in 2009. After ten years, the number of its
employees decreased to three and the company directed its
efforts toward the development of its hologram-on-a-catheter
biosensor. As the company entered 2012, it was no longerThis journal is © The Royal Society of Chemistry 2015
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View Article Onlineable to pay its patent maintenance fees, and it was eventually
shut down in 2013.
8. Conclusions
Technology startups from academic institutions have become
a major driving force behind high-tech clusters and the
global economy. Hence, academic institutions have created
technology transfer offices to exploit the knowledge for creat-
ing high-value products. However, optimization of commer-
cialization strategies can enable the inventors and academic
institutions to extract the maximum value from the inven-
tions and know-how.
The process of turning an idea into a product begins with
IP protection, where building an IP portfolio around the core
technologies creates a competitive advantage. The protected
idea is an unrealized technology, however, and does not hold
a value until it is transferred into an extended product, which
requires formulating a commercialization strategy. If the
technology is licensed by a startup, entrepreneurs should
then develop commercialization, financing, marketing and
exit strategies with several contingency plans to mitigate the
uncertainty of technology.
The initial technology should undergo productization to
turn the proof of concept into a viable, commercial product.
The most critical step in creating a product is to check the
assumptions about customer behavior. Hence, customer
development through obtaining feedback from potential cus-
tomers and validating the commercialization strategy should
be carried out in parallel with product development. Entre-
preneurs should not wait for the customers to come to them;
they must take the lead.
In product development, a typical startup requires multi-
ple investment rounds including seed funding and venture
capital. Having a motivated team, a global market need, and
a working prototype with validated customer base can
increase the potential for obtaining investment. Investors will
be more likely to invest in a company that has already raised
initial seed funds. The funding opportunities for the upcom-
ing rounds should be sought in advance, and the startups
need to bootstrap to reduce the outgoing cash flow. However,
a balance should be struck between taking too much or less
investment.
Entrepreneurs should also have a marketing plan, with a
specific strategy to cross the chasm and gain the attention of
the early majority customer base. Even products that are sci-
entifically sound with an obvious unmet need may not be
able to cross the chasm without effective marketing if, for
example, the global market demand is prohibitive.
Entrepreneurs should plan an exit strategy, such as an
acquisition, merger, or IPO. This requires maintaining a
vision and questioning the company's vision while making
the company's technology attractive to large corporations and
the general public. Achieving a clear vision is an interactive
process in product and consumer development, which
requires pivoting the commercialization strategy multipleThis journal is © The Royal Society of Chemistry 2015times. The execution of these tasks can only be achieved with
strong leadership that can make quick objective decisions.
The difference between successful entrepreneurs and
those who are not boils down to the concept of productivity.
To achieve this skill set, entrepreneurs may need to fail many
times to refine their work habits and test their will to create
an extended product that will serve the society. Hence, suc-
cessful entrepreneurs are persistent and are motivated by
impact of their ideas. To become productive, all successful
entrepreneurs understand that time is the most important
commodity, and they apply the best of their ability to achieve
every single milestone in the shortest time possible to create
a positive social impact.
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